The federal Cancer Drug Coverage Parity Act will dramatically improve the lives of cancer patients. Patients who previously could not afford these treatments will be able to access their life-saving effects. It will also make cancer treatments more practical for patients living in rural and underserved areas by reducing the need to drive long distances for a nurse or doctor to administer treatment.
Newly Approved POMALYST® (Pomalidomide) Is an Oral Therapy with Demonstrated Overall Survival Benefit in Patients Who Have Had Multiple Prior Treatments
print
back to top